Many drugmakers are still in the earliest stages of incorporating digital endpoints into the plodding process of drug development. But one small company is moving full throttle with its effort.

WARREN, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the pricing of offerings for an aggregate of ...